We are live on ! Find out more
TBRA

Tobira Therapeutics, Inc. Common Stock
TBRA

Delisted

TBRA was delisted on the 31st of October, 2016.

47 hedge funds and large institutions have $5.9M invested in Tobira Therapeutics, Inc. Common Stock in 2014 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 13 increasing their positions, 14 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more call options, than puts

Call options by funds: $4K | Put options by funds: $4K

7% less repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 14

4% less funds holding

Funds holding: 4947 (-2)

15% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 13

91% less capital invested

Capital invested by funds: $64.6M → $5.9M (-$58.7M)

Holders
47
Holders Change
-2
Holders Change %
-4.08%
% of All Funds
1.36%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
11
Increased
13
Reduced
14
Closed
13
Calls
$4K
Puts
$4K
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
BI
1
BVF Inc
California
$2.95M
PAM
2
Panagora Asset Management
Massachusetts
$635K +$1.23M +62,452 New
Vanguard Group
3
Vanguard Group
Pennsylvania
$614K +$84.9K +4,299 +8%
BFA
4
BlackRock Fund Advisors
California
$413K -$33.2K -1,680 -4%
Northern Trust
5
Northern Trust
Illinois
$188K +$269K +13,618 +282%
BIT
6
BlackRock Institutional Trust
California
$141K -$250K -12,660 -48%
Geode Capital Management
7
Geode Capital Management
Massachusetts
$123K +$336 +17 +0.1%
TDC
8
Thompson Davis & Co
Virginia
$114K +$222K +11,222 New
TCIM
9
TIAA CREF Investment Management
New York
$78K +$23K +1,165 +18%
Bank of New York Mellon
10
Bank of New York Mellon
New York
$74K
Charles Schwab
11
Charles Schwab
California
$69K +$83K +4,200 +167%
State Street
12
State Street
Massachusetts
$67K +$40.2K +2,034 +44%
BIM
13
BlackRock Investment Management
Delaware
$49K -$99 -5 -0.1%
TRCT
14
Tower Research Capital (TRC)
New York
$47K +$63.5K +3,216 +226%
SG Americas Securities
15
SG Americas Securities
New York
$46K +$90.1K +4,562 New
California Public Employees Retirement System
16
California Public Employees Retirement System
California
$44K
California State Teachers Retirement System (CalSTRS)
17
California State Teachers Retirement System (CalSTRS)
California
$32K +$356 +18 +0.6%
BIA
18
Biondo Investment Advisors
Pennsylvania
$26K -$544K -27,525 -92%
Jane Street
19
Jane Street
New York
$25K -$31.7K -1,604 -39%
TA
20
Teachers Advisors
New York
$24K
Goldman Sachs
21
Goldman Sachs
New York
$23K -$7.63K -386 -15%
RhumbLine Advisers
22
RhumbLine Advisers
Massachusetts
$16K +$3.24K +164 +12%
NFA
23
Nationwide Fund Advisors
Ohio
$13K
TC
24
TFS Capital
Pennsylvania
$12K -$173K -8,759 -88%
U
25
UBS
Switzerland
$12K +$20.2K +1,021 +817%

TBRA Hedge Fund Activity: Q3 2014 in Review

47 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in Tobira Therapeutics, Inc. Common Stock (TBRA) for Q3 2014, worth a combined $5.9M — down 91% from $64.6M a quarter earlier.

Sellers outnumbered buyers: 13 funds closed out of TBRA and 11 opened new positions — a net loss of 2 holders — while 14 trimmed existing stakes and 13 added.

The largest buyer was Sabby Management, adding an estimated $1.93M. The largest seller was Gilder Gagnon Howe & Co, exiting entirely with an estimated $15.4M sold.

  • 47 institutional investors held Tobira Therapeutics, Inc. Common Stock (TBRA) as of Q3 2014, down from 49 in Q2 2014.
  • Funds reported $5.9M of Tobira Therapeutics, Inc. Common Stock stock for Q3 2014, down 91% quarter-over-quarter.
  • 11 funds opened new Tobira Therapeutics, Inc. Common Stock positions in Q3 2014 and 13 closed out, a net change of -2 holders.
  • The largest Tobira Therapeutics, Inc. Common Stock buyer in Q3 2014 was Sabby Management, an estimated $1.93M added.
  • The largest Tobira Therapeutics, Inc. Common Stock seller in Q3 2014 was Gilder Gagnon Howe & Co, an estimated $15.4M sold.

Based on aggregated 13F filings for Q3 2014.